Ingo Elfering

Ingo Elfering is an experienced executive in the field of information technology and digital transformation, currently serving as the Group CIO at Fresenius Group, a global healthcare company.1 His career spans several high-profile roles in the pharmaceutical and healthcare industries, showcasing his expertise in IT leadership and innovation.

Career Highlights

Current Role: Elfering has been the Group CIO at Fresenius Group since October 2022, based in the Philadelphia, Pennsylvania area.1 In this position, he is responsible for modernizing IT and driving digitalization in healthcare.1

Previous Positions:

• Fresenius Group: From July 2020 to September 2022, he held the dual role of Group CIO and CEO of Fresenius Digital Technology.1
• Bayer Crop Science: Served as CIO, Head of Digital Transformation, and Member of the Crop Science Executive Leadership Team from October 2019 to July 2020.1
• Indivior: Held the position of Chief Information and Innovation Officer from November 2014 to September 2018.1
• GlaxoSmithKline: Worked in various roles, including Chief Architect and VP IT Strategy (2008-2010) and VP eBusiness and Global eIT (2000-2005).1

Achievements and Expertise

Elfering has demonstrated significant accomplishments throughout his career:

• Led the demerger of Indivior from Reckitt Benckiser, establishing a complete greenfield IT environment globally.1
• Implemented SAP S4/HANA-based Global Single Instance ERP solutions.1
• Drove cloud transformation initiatives, including moving 29 system landscapes and over 130 applications to the cloud in just 15 months at Fresenius.3
• Recognized for his leadership and vision in cloud transformation.2
• Actively involved in implementing new IT operating models and fostering teamwork across global teams.4

Ingo Elfering is known for his executive vision and ability to create supporting organizations for IT services delivery in large global companies.1 His expertise spans areas such as digital transformation, IT strategy, and innovation in the healthcare and pharmaceutical sectors.